- May 24, 2013
- Taiho Pharmaceutical Co., Ltd.
New Plant Constructed in Tokushima Prefecture
To Serve as Production Center for Anti-cancer Drugs
Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo; President: Masayuki Kobayashi; hereafter, "Taiho Pharmaceutical") announced today that construction of a new production plant in Tokushima Prefecture, Japan, which had commenced in January 2012, has been completed.
The new plant will serve as a production center for anti-cancer drugs. The plant was built on a site of approximately 290,000 square meters in Tokushima City and Kitajima, a town in the Itano district of Tokushima Prefecture.
Taiho Pharmaceutical constructed a factory furnished with state-of-the-art equipment for making solid preparations, as well as buildings to house offices and a quality control center. The company also gave consideration to local citizens and the surrounding environment when designing the plant, preparing a park and promenade lined with cherry trees around the site to provide neighborhood residents with areas for taking a pleasant stroll. The park can also be used as a public evacuation site in the event of an emergency.
With the construction of this new facility, Taiho Pharmaceutical will continue striving to make positive contributions to medical patients and healthcare professionals around the world through its pharmaceutical business, especially in the field of anti-cancer drugs.
Details of the new production facility are listed below.
Overview of the new production facility
| Name: | Taiho Pharmaceutical Kitajima Plant |
|---|---|
| Address: | 1 – 1 Inai, Takabo, Kitajima-cho, Itano-gun, Tokushima Prefecture, Japan |
| Total area: | Approximately 290,000 square meters |
| Construction commencement: | January 2012 |
| Construction completion: | May 2013 |
| Operation commencement: | May 2014 |
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.